APA (7th ed.) Citation

ADI, v. A., N, A., M, K., A, P., K, M., L, S., . . . SE, G. (2023). Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 41(3), 239. https://doi.org/10.1007/s40273-023-01244-z

Chicago Style (17th ed.) Citation

ADI, van Asselt, et al. "Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." PharmacoEconomics 41, no. 3 (2023): 239. https://doi.org/10.1007/s40273-023-01244-z.

MLA (9th ed.) Citation

ADI, van Asselt, et al. "Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." PharmacoEconomics, vol. 41, no. 3, 2023, p. 239, https://doi.org/10.1007/s40273-023-01244-z.